Bertrand Liang - Purple Biotech Chief Medical Officer
| KTOV Stock | ILA 5.90 0.30 4.84% |
Insider
Bertrand Liang is Chief Medical Officer of Purple Biotech since 2020.
| Age | 60 |
| Tenure | 5 years |
| Phone | 972 3 933 3121 |
| Web | http://www.kitovpharma.com |
Purple Biotech Management Efficiency
The company has return on total asset (ROA) of (0.0915) % which means that it has lost $0.0915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9204) %, meaning that it generated substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Yoni Barel | Azorim Investment Development | 32 | |
| Levi Shtresler | Azorim Investment Development | 52 | |
| Inbal Korland | Oron Group Investments | N/A | |
| Nava Levy | Analyst IMS Investment | ||
| Noam Rokach | Analyst IMS Investment | 52 | |
| Nir Kelner | Adgar Investments and | 46 | |
| Daniel Shapira | Oron Group Investments | 69 | |
| Alon Agushevich | Analyst IMS Investment | 61 | |
| Eldad Cohen | Analyst IMS Investment | 49 | |
| Itay Meroz | WhiteSmoke Software | 53 | |
| Itay Kantrowitz | Adgar Investments and | 59 | |
| Rafi Niv | Meitav Dash Investments | 60 | |
| Sigal Halevy | Azorim Investment Development | N/A | |
| Erik Daniel | Oron Group Investments | N/A | |
| Roni Kleinfeld | WhiteSmoke Software | 62 | |
| Oded Bloom | Oron Group Investments | 58 | |
| Chris Tambakis | Adgar Investments and | N/A | |
| Victor Braha | Analyst IMS Investment | 49 | |
| Frank Cohen | Analyst IMS Investment | 46 | |
| Amit Greener | WhiteSmoke Software | N/A | |
| Guy Harel | WhiteSmoke Software | N/A | |
Management Performance
| Return On Equity | -0.92 | |||
| Return On Asset | -0.0915 |
Purple Biotech Leadership Team
Elected by the shareholders, the Purple Biotech's board of directors comprises two types of representatives: Purple Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Purple. The board's role is to monitor Purple Biotech's management team and ensure that shareholders' interests are well served. Purple Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Purple Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Itzhak Israel, Chief Executive Officer & Director | ||
| Steven Steinberg, Independent Director | ||
| Gil BenMenachem, Vice President - Business Development | ||
| Michael Schickler, Head of Clinical Operations | ||
| CPA MBA, Strategic Director | ||
| Arie Weber, Independent Director | ||
| Bertrand Liang, Chief Medical Officer | ||
| Yisrael Gewirtz, Internal Auditor | ||
| Ran Tzror, Independent Director | ||
| Gil Efron, Deputy Chief Executive Officer, Chief Financial Officer | ||
| Simcha Rock, CFO, Director | ||
| Eric Rowinsky, Chairman of the Board | ||
| Ido Agmon, Independent Director | ||
| Gil CPA, Deputy CFO | ||
| Isaac Israel, CEO Director | ||
| Revital SternRaff, Independent Director | ||
| Avraham BenTzvi, General Counsel, Secretary | ||
| Hadas Reuveni, Founder and Chief Technology Officer of TyrNovo (a subsidiary) |
Purple Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Purple Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.92 | |||
| Return On Asset | -0.0915 | |||
| Operating Margin | (7.54) % | |||
| Shares Outstanding | 172.11 M | |||
| Shares Owned By Insiders | 0.12 % | |||
| Shares Owned By Institutions | 1.22 % | |||
| Price To Earning | (364.21) X | |||
| Price To Book | 1.27 X | |||
| Price To Sales | 16.36 X | |||
| Revenue | 1000 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Purple Stock
When determining whether Purple Biotech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Purple Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Purple Biotech Stock. Highlighted below are key reports to facilitate an investment decision about Purple Biotech Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.